EP Patent

EP3957632A1 — Meglumine salt and crystalline forms thereof of a drug (delafloxacin)

Assigned to AbbVie Inc · Expires 2022-02-23 · 4y expired

What this patent protects

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

USPTO Abstract

A crystalline form of a drug, ways to make it, compositions containing it and methods of treatment of diseases and inhibition of adverse physiological events using it are disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
EP3957632A1
Jurisdiction
EP
Classification
—
Expires
2022-02-23
Drug substance claim
No
Drug product claim
No
Assignee
AbbVie Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.